PL 6983

PL-6983 is a synthetic peptide and selective MC₄ receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models. The drug has reportedly been in pre-clinical development for all medical indications since 2008.[1] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[2] The chemical structure of PL-6983 has yet to be made public.